What Avisi Technologies does

Avisi Technologies is a clinical-stage ophthalmic medical device company developing nanotechnology-enabled implants to treat open-angle glaucoma and related vision-loss conditions. Its core technology is a proprietary metamaterial platform combining alumina and Parylene-C, originally invented at the University of Pennsylvania's Singh Center for Nanotechnology, manufactured using MEMS (Micro-Electro-Mechanical Systems) micro-fabrication techniques to produce devices roughly 5 microns thick. The lead product, VisiPlate, is an ultrathin multichannel aqueous shunt designed to drain aqueous fluid from the anterior chamber to the subconjunctival space while avoiding the fibrotic scarring that causes failure of incumbent surgeries. The portfolio also includes VisiPlate-S, a suprachoroidal drainage device for mild-to-moderate glaucoma implanted during cataract surgery, and V-001, an early-stage sustained intraocular drug-delivery platform funded by NSF SBIR Phase II and IIB grants.

The company operates a vertical go-to-market targeting ophthalmologists, glaucoma specialists, and hospital/ASC-based surgical departments. Marketing is conducted through medical conferences (AAO, ASCRS, ESCRS, AGS, ARVO), peer-reviewed publications, key opinion leader relationships, and an active LinkedIn presence. Distribution is currently limited to investigational device shipments to 16 SAPPHIRE pivotal trial sites across 8 US states, with planned direct field sales to hospitals and ambulatory surgery centers post-FDA approval.

The business is pre-revenue. VisiPlate received FDA Investigational Device Exemption approval in October 2025, the first US patient was implanted in December 2025, and the company closed a $10.7M Series A in February 2026 (total funding ~$21.7M) to fund the SAPPHIRE pivotal trial and pipeline development. Reported 12-month VITA Trial outcomes — 42.6% mean diurnal IOP reduction and 46.7% medication-free patients with no serious adverse events — are the primary commercial validation to date. The 165-patient SAPPHIRE pivotal trial has an estimated completion date of October 2027.

Name

Avisi Technologies

Legal name

Avisi Technologies, Inc.

Website

https://avisitech.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Avisi Technologies is a clinical-stage medical device company developing ultrathin nanotechnology-based glaucoma implants, including the VisiPlate aqueous shunt, targeting ophthalmologists and glaucoma specialists at hospitals and ambulatory surgery centers.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)

akta.pro primary industry

Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)

akta.pro secondary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Glaucoma treatment devices
• Ophthalmic medical devices
• Intraocular pressure management
• Aqueous shunts
• Nanotechnology ophthalmology

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales (Pre-commercial): Avisi Technologies is currently a clinical-stage company with no commercial revenue. The company is conducting FDA clinical trials for VisiPlate. Once approved, the company expects to generate revenue through direct sales of its VisiPlate aqueous shunt devices to hospitals, ambulatory surgery centers, and ophthalmology practices treating glaucoma patients.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Avisi Technologies develops nanotechnology-enabled ophthalmic medical devices for the treatment of glaucoma and related eye conditions. Its core offering is VisiPlate, an investigational ultrathin (~5 micron) multichannel aqueous shunt made of patented alumina and Parylene-C metamaterial that controls intraocular pressure via redundant microchannels, with additional pipeline products including VisiPlate-S (suprachoroidal drainage device) and V-001 (sustained intraocular drug-delivery platform). The devices are manufactured using MEMS micro-fabrication techniques invented at the University of Pennsylvania.

Product overview

Avisi Technologies is a clinical-stage ophthalmic medical device company developing a portfolio of glaucoma treatment products leveraging proprietary nanotechnology and metamaterial technology. The core product is VisiPlate, an ultrathin multichannel aqueous shunt for moderate-severe glaucoma. This is complemented by VisiPlate-S, a suprachoroidal device designed for mild-moderate glaucoma during cataract surgery, and V-001, a sustained intraocular drug-delivery platform for dropless therapeutic delivery. The company uses MEMS (Micro-Electro-Mechanical Systems) manufacturing and advanced micro-fabrication techniques developed at the University of Pennsylvania.

Differentiator

Problem solved

Functional benefit

Products and services

• VisiPlate VisiPlate is an investigational ultrathin multichannel aqueous shunt device designed to lower intraocular pressure in patients with open-angle glaucoma. The device is made of a patented metamaterial composition of alumina and Parylene-C, approximately 5 microns thick (several times thinner than a human hair), with multiple redundant microchannels that control aqueous drainage from the anterior chamber to the subconjunctival space. The non-fibrotic material design minimizes the scarring and blockage that causes failure of existing glaucoma surgical treatments.
• VisiPlate-S VisiPlate-S is an investigational suprachoroidal drainage device designed for placement in the suprachoroidal space during cataract surgery to treat patients with mild-to-moderate primary open-angle glaucoma. The device is ultrathin, minimally invasive, soft and flexible, featuring a non-scarring design with a network of microchannels that create aqueous outflow through the suprachoroidal space via the uveoscleral pathway.
• V-001 V-001 is a thin-film sustained intraocular drug-delivery platform designed to provide controlled, sustained release of therapeutics (including dexamethasone) in the anterior chamber. The platform aims to create a dropless patient experience by reducing the compliance burden associated with topical eye drops for glaucoma and other eye disease treatment.

Quantifiable outcome

• 42.6% reduction in mean diurnal IOP at 12 months (from 24.1 to 13.1 mmHg)
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Johnson & Johnson JLABScoreStrategic or Co-development Partner · 1 January 2024Avisi is a member of JLABS, Johnson & Johnson's premier life science incubator. The company was part of the inaugural JPOD resident cohort receiving support from concept to commercialization.
• UCSF Rosenman Innovator ProgramsupportingStrategic or Co-development Partner · 1 January 2020Selected for the Rosenman Innovators program supporting medtech startups with mentorship and resources for commercialization.
• University of PennsylvaniacoreStrategic or Co-development Partner · 1 January 2017VisiPlate technology was invented at the University of Pennsylvania through the Singh Center for Nanotechnology. Avisi was founded through the Y-Prize program and received support from Penn Engineering labs. Scientific advisors hail from Penn's Scheie Eye Institute.
• MedTech Innovator AcceleratorsupportingStrategic or Co-development Partner · 1 January 2017Alumni of the MedTech Innovator Accelerator program, which provides mentorship and support for medical technology companies.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Glaukos Corporation: Glaukos is the pioneer and market leader in MIGS devices (iStent family) for open-angle glaucoma. It is the most directly comparable peer to Avisi's VisiPlate, addressing the same patient population with similarly minimally invasive surgical implants targeting IOP reduction.
• Sight Sciences: Sight Sciences markets the OMNI and Sustain systems, MIGS devices for glaucoma that combine trabecular and suprachoroidal outflow pathways. It directly competes with Avisi's VisiPlate and VisiPlate-S in the same ophthalmic surgical channels.
• New World Medical: New World Medical manufactures traditional glaucoma drainage devices (Ahmed, Baerveldt implants) that compete with VisiPlate in moderate-to-severe open-angle glaucoma. It is a relevant peer for surgical shunts in the same procedural category.

Broad incumbents

• Alcon: Alcon is a global ophthalmic medtech incumbent with a broad surgical and vision-care portfolio. It acquired Ivantis (Hydrus Microstent, a suprachoroidal MIGS device directly comparable to VisiPlate-S) and competes broadly across glaucoma surgical devices.
• AbbVie (Allergan Aesthetics / Eye Care): AbbVie, through its Allergan acquisition, markets the Xen Gel Stent (subconjunctival drainage device) and a broad ophthalmic pharmaceutical portfolio. Xen is the closest large-pharma competitor to VisiPlate in mechanism and indication.
• Johnson & Johnson Vision: Johnson & Johnson Vision is a leading ophthalmic medtech incumbent and the operator of JLABS, where Avisi is a resident company. J&J Vision sells cataract surgical products and has strategic interest in MIGS/glaucoma surgical adjacencies, making it both a competitor and potential acquirer.
• Bausch + Lomb: Bausch + Lomb is a major ophthalmic medtech incumbent with surgical and pharmaceutical glaucoma offerings. Its broad portfolio and global distribution make it a strategic competitor and potential acquirer of emerging glaucoma device companies like Avisi.
• Santen Pharmaceutical: Santen is a Japan-based global ophthalmology specialty pharmaceutical and device company with a substantial glaucoma franchise (including the InnFocus MicroShunt acquired from InnFocus). It is a strategic peer for both device and pharmaceutical glaucoma offerings overlapping Avisi's pipeline.

Emerging players

• Iantrek: Iantrek is an early-to-growth-stage ophthalmic device company developing micro-invasive glaucoma surgical technologies, including canaloplasty and suprachoroidal approaches. It overlaps with Avisi in MIGS innovation targeting the same glaucoma surgeon customer base.
• MicroOptx: MicroOptx is a clinical-stage ophthalmic medtech company developing a suprachoroidal glaucoma drainage implant. It is a direct emerging-stage peer to Avisi's VisiPlate-S in the same suprachoroidal mechanism of action.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/avisi_tech
• YouTubeyoutube.com/@avisitechnologies9154
• Facebookfacebook.com/avisitech
• LinkedInlinkedin.com/company/avisi-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds11 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avisi Technologies